FY2025 Earnings Forecast for Alector Issued By William Blair

Key Points

• William Blair has upgraded Alector's FY2025 EPS estimate to ($1.52) per share, an improvement from the previous estimate of ($1.62).
• The current consensus estimate for Alector's full-year earnings is ($1.88) per share, indicating a projected earnings opportunity.
• Alector's stock has recently experienced an 8.7% drop, currently trading at $1.47 with a market cap of $148.78 million.

Alector, Inc. (NASDAQ:ALEC - Free Report) - Stock analysts at William Blair lifted their FY2025 EPS estimates for Alector in a research note issued to investors on Wednesday, October 22nd. William Blair analyst M. Minter now forecasts that the company will earn ($1.52) per share for the year, up from their previous forecast of ($1.62). William Blair has a "Market Perform" rating on the stock. The consensus estimate for Alector's current full-year earnings is ($1.88) per share. William Blair also issued estimates for Alector's Q4 2025 earnings at ($0.39) EPS, Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.33) EPS and FY2026 earnings at ($1.31) EPS.

ALEC has been the subject of several other research reports. Wall Street Zen lowered shares of Alector from a "hold" rating to a "sell" rating in a research note on Friday, September 26th. Mizuho set a $1.50 target price on shares of Alector and gave the company a "neutral" rating in a research note on Wednesday. Cowen lowered shares of Alector to a "hold" rating in a research note on Wednesday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Alector in a research note on Wednesday, October 8th. Finally, TD Cowen lowered shares of Alector from a "buy" rating to a "hold" rating in a research note on Wednesday. One equities research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, Alector presently has a consensus rating of "Reduce" and a consensus price target of $3.00.

Alector Stock Down 8.7%

ALEC stock opened at $1.47 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.78 and a quick ratio of 3.78. Alector has a 1-year low of $0.87 and a 1-year high of $6.14. The firm has a fifty day moving average price of $2.79 and a two-hundred day moving average price of $1.88. The firm has a market cap of $148.78 million, a price-to-earnings ratio of -1.27 and a beta of 0.99.

Alector (NASDAQ:ALEC - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. Alector had a negative net margin of 142.10% and a negative return on equity of 112.06%. The firm had revenue of $7.87 million during the quarter, compared to analyst estimates of $2.76 million. Alector has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Alector

Several institutional investors have recently modified their holdings of the company. HBK Sorce Advisory LLC bought a new position in shares of Alector during the third quarter worth about $34,000. Hamilton Lane Advisors LLC bought a new position in shares of Alector during the third quarter worth about $43,000. State of Wyoming grew its position in Alector by 13.4% in the 2nd quarter. State of Wyoming now owns 223,092 shares of the company's stock valued at $312,000 after buying an additional 26,278 shares in the last quarter. Boothbay Fund Management LLC grew its position in Alector by 67.2% in the 2nd quarter. Boothbay Fund Management LLC now owns 458,863 shares of the company's stock valued at $642,000 after buying an additional 184,503 shares in the last quarter. Finally, Bridgeway Capital Management LLC bought a new position in Alector in the 2nd quarter valued at about $161,000. Institutional investors own 85.83% of the company's stock.

Insider Activity at Alector

In other news, Director Paula Hammond sold 14,000 shares of the company's stock in a transaction dated Tuesday, August 26th. The shares were sold at an average price of $2.36, for a total transaction of $33,040.00. Following the completion of the transaction, the director owned 74,909 shares in the company, valued at approximately $176,785.24. This represents a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 9.70% of the company's stock.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.